Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos

PURPOSE Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease caused by the human T-cell leukemia virus type 1. Real-world data of ATLL in Latin America are lacking. PATIENTS AND METHODS We analyzed patients with ATLL (acute, lymphomatous, chronic, and smoldering) encountered in 11 Latin American countries between 1995 and 2019. Treatment response was assessed according to the 2009 consensus report. Survival curves were estimated using the Kaplan-Meier method and log-rank test. RESULTS We identified 253 patients; 226 (lymphomatous: n = 122, acute: n = 73, chronic: n = 26, and smoldering: n = 5) had sufficient data for analysis (median age 57 years). Most patients with ATLL were from Peru (63%), Chile (17%), Argentina (8%), and Colombia (7%). Hypercalcemia was positively associated with acute type (57% v lymphomatous 27%, P = .014). The median survival times (months) were 4.3, 7.9, 21.1, and not reached for acute, lymphomatous, chronic, and smoldering forms, with 4-year survival rates of 8%, 22%, 40%, and 80%, respectively. First-line zidovudine (AZT)-interferon alfa (IFN) resulted in an overall response rate of 63% (complete response [CR] 24%) for acute. First-line chemotherapy yielded an overall response rate of 41% (CR 29%) for lymphomatous. CR rate was 42% for etoposide, cyclophosphamide, vincristine, doxorubicin, and prednisone versus 12% for cyclophosphamide, vincristine, doxorubicin, and prednisone–like regimen (P < .001). Progression-free survival at 1 year for acute type patients treated with AZT-IFN was 67%, whereas 2-year progression-free survival in lymphomatous type patients who achieved CR after chemotherapy was 77%. CONCLUSION This study confirms Latin American ATLL presents at a younger age and has a high incidence of lymphomatous type, low incidence of indolent subtypes, and worse survival rates as compared with Japanese patients. In aggressive ATLL, chemotherapy remains the preferred choice for lymphomatous favoring etoposide-based regimen (etoposide, cyclophosphamide, vincristine, doxorubicin, and prednisone), whereas AZT-IFN remains a good first-line option for acute subtype.

[1]  A. Vallinoto,et al.  The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil , 2020, Retrovirology.

[2]  G. Taylor,et al.  Adult T‐cell leukaemia/lymphoma in Brazil: A rare disease or rarely diagnosed? , 2019, British journal of haematology.

[3]  J. Castillo,et al.  Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL) , 2019, Blood.

[4]  E. Anguita,et al.  Human T‐Cell Lymphotropic Virus Type 1 and associated diseases in Latin America , 2019, Tropical medicine & international health : TM & IH.

[5]  M. Garcia-Bereguiain,et al.  A high prevalence of human T-lymphotropic virus (HTLV 1/2) infection among Afro-descendants, Esmeraldas province, Ecuador – need for the implementation of surveys and control programs , 2019, Infection and drug resistance.

[6]  M. C. D. de Almeida,et al.  Evidence of New Endemic Clusters of Human T-Cell Leukemia Virus (HTLV) Infection in Bahia, Brazil , 2019, Front. Microbiol..

[7]  K. Pradhan,et al.  North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. , 2018, Blood.

[8]  G. Barber,et al.  Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. , 2018, Blood advances.

[9]  D. Enríquez,et al.  New Prognostic Classification for Adult T Cell Lymphoma/Leukemia Based on Hypercalcemia and Neutrophil-to-Lymphocyte Ratio , 2017 .

[10]  O. Pritsch,et al.  Infección por virus linfotrópico de células T humanas (HTLV) en Uruguay: identificación de problemas , 2017 .

[11]  J. Cuellar,et al.  Prevalencia del Virus Linfotrópico de células T humanas HTLV I/II en donantes sangre , 2017 .

[12]  A. Bittencourt,et al.  Adult T-cell leukemia/lymphoma in South and Central America and the Caribbean: systematic search and review , 2017, International journal of STD & AIDS.

[13]  A. Verma,et al.  Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy , 2016, Oncotarget.

[14]  S. Hanada,et al.  Treatment and survival among 1594 patients with ATL. , 2015, Blood.

[15]  J. Casseb,et al.  ORIGIN AND PREVALENCE OF HUMAN T-LYMPHOTROPIC VIRUS TYPE 1 (HTLV-1) AND TYPE 2 (HTLV-2) AMONG INDIGENOUS POPULATIONS IN THE AMERICAS , 2015, Revista do Instituto de Medicina Tropical de Sao Paulo.

[16]  M. Satake,et al.  The incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type 1 carriers in Japan , 2015, Leukemia & lymphoma.

[17]  L. Trümper,et al.  984TiPPHASE 3 TRIAL OF BRENTUXIMAB VEDOTIN AND CHP VERSUS CHOP IN THE FRONTLINE TREATMENT OF PATIENTS (PTS) WITH CD30+ MATURE T-CELL LYMPHOMAS (MTCL). , 2014, Annals of Oncology.

[18]  J. Castillo,et al.  Adult T-Cell Leukemia/Lymphoma in Peru: A Report of 120 Cases , 2012 .

[19]  A. Gessain,et al.  Epidemiological Aspects and World Distribution of HTLV-1 Infection , 2012, Front. Microbio..

[20]  J. Castillo,et al.  Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma. , 2011, Leukemia research.

[21]  A. Bazarbachi,et al.  Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  V. Seshan,et al.  A critical analysis of prognostic factors in North American patients with human T‐cell lymphotropic virus type‐1‐associated adult T‐cell leukemia/lymphoma , 2010, Cancer.

[23]  K. Yamaguchi,et al.  Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Anne-Mieke Vandamme,et al.  Human T-lymphotropic virus 1: recent knowledge about an ancient infection. , 2007, The Lancet. Infectious diseases.

[25]  I. Lossos,et al.  IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. , 2007, Blood.

[26]  M. Aboud,et al.  Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity , 2004, Retrovirology.

[27]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[28]  A. Sill,et al.  Geographic diversity of adult t‐cell leukemia/lymphoma in Brazil , 1999, International journal of cancer.

[29]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[30]  M. Yoshida,et al.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Reitz,et al.  Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia , 1981, Nature.

[32]  Y. E. Caribe,et al.  Suministro de sangre para transfusiones en los países de América Latina y el Caribe 2016-2017 , 2020 .